{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T18:20:26Z","timestamp":1774117226910,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-024-10432-8","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T03:21:21Z","timestamp":1724728881000},"page":"1235-1238","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Embracing an era of targeted combination therapy for heart failure with preserved ejection fraction"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2223-7215","authenticated-orcid":false,"given":"Satoshi","family":"Shoji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J","family":"Greene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J","family":"Mentz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"key":"10432_CR1","doi-asserted-by":"crossref","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the american college of cardiology\/american heart association joint committee on clinical practice guidelines.\u00a0https:\/\/www.ahajournals.org\/doi\/10.1161\/CIR.0000000000001063","DOI":"10.1161\/CIR.0000000000001063"},{"key":"10432_CR2","first-page":"2129","volume":"37","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M et al (2023) 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 37:2129\u20132200","journal-title":"Eur Heart J"},{"key":"10432_CR3","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/nejmoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS et al (2019) Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med 381:1609\u20131620. https:\/\/doi.org\/10.1056\/nejmoa1908655","journal-title":"N Engl J Med"},{"key":"10432_CR4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jacc.2019.11.003","volume":"75","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan M, Claggett BL, Desai AS et al (2020) Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril\/Valsartan Compared With Valsartan in HFpEF. J Am Coll Cardiol 75:245\u2013254. https:\/\/doi.org\/10.1016\/j.jacc.2019.11.003","journal-title":"J Am Coll Cardiol"},{"key":"10432_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","volume":"82","author":"RJ Mentz","year":"2023","unstructured":"Mentz RJ, Ward JH, Hernandez AF et al (2023) Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure. J Am Coll Cardiol 82:1\u201312. https:\/\/doi.org\/10.1016\/j.jacc.2023.04.019","journal-title":"J Am Coll Cardiol"},{"key":"10432_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/eurheartj\/ehad344","volume":"00","author":"M Vaduganathan","year":"2023","unstructured":"Vaduganathan M, Mentz RJ, Claggett BL et al (2023) Sacubitril\/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. Eur Heart J 00:1\u201312. https:\/\/doi.org\/10.1093\/eurheartj\/ehad344","journal-title":"Eur Heart J"},{"key":"10432_CR7","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF et al (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370:1383\u20131392. https:\/\/doi.org\/10.1056\/NEJMoa1313731","journal-title":"N Engl J Med"},{"key":"10432_CR8","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","volume":"37","author":"SD Solomon","year":"2016","unstructured":"Solomon SD, Claggett B, Lewis EF et al (2016) Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 37:455\u2013462. https:\/\/doi.org\/10.1093\/eurheartj\/ehv464","journal-title":"Eur Heart J"},{"key":"10432_CR9","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/nejmoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD et al (2020) Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 383:2219\u20132229. https:\/\/doi.org\/10.1056\/nejmoa2025845","journal-title":"N Engl J Med"},{"key":"10432_CR10","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/nejmoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R et al (2021) Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 385:2252\u20132263. https:\/\/doi.org\/10.1056\/nejmoa2110956","journal-title":"N Engl J Med"},{"key":"10432_CR11","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/nejmoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA et al (2023) Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med 389:1069\u20131084. https:\/\/doi.org\/10.1056\/nejmoa2306963","journal-title":"N Engl J Med"},{"key":"10432_CR12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2307563","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM et al (2023) Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. https:\/\/doi.org\/10.1056\/nejmoa2307563","journal-title":"N Engl J Med"},{"key":"10432_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/oby.23621","volume":"31","author":"I Lingvay","year":"2023","unstructured":"Lingvay I, Brown-Frandsen K, Colhoun HM et al (2023) Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity 31:111\u2013122. https:\/\/doi.org\/10.1002\/oby.23621","journal-title":"Obesity"},{"key":"10432_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1161\/CIRCULATIONAHA.114.010637","volume":"131","author":"SJ Shah","year":"2015","unstructured":"Shah SJ, Katz DH, Selvaraj S et al (2015) Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 131:269\u2013279. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.010637","journal-title":"Circulation"},{"key":"10432_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1002541","volume":"15","author":"J Tromp","year":"2018","unstructured":"Tromp J, Tay WT, Ouwerkerk W et al (2018) Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. PLoS Med 15:1\u201322. https:\/\/doi.org\/10.1371\/journal.pmed.1002541","journal-title":"PLoS Med"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-024-10432-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-024-10432-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-024-10432-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T19:03:26Z","timestamp":1728155006000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-024-10432-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":15,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["10432"],"URL":"https:\/\/doi.org\/10.1007\/s10741-024-10432-8","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]},"assertion":[{"value":"19 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Author Stephen J Greene is an Associate Editor of the journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"Dr. Greene has received research support from the Duke University Department of Medicine Chair\u2019s Research Award, American Heart Association, Amgen, AstraZeneca, Boehinger Ingelheim, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; has served on advisory boards or as consultant for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Corcept, Corteria Pharmaceuticals, CSL Vifor, Cytokinetics, Eli Lilly, Lexicon, Merck, Novo Nordisk, Otsuka, Roche Diagnostics, Sanofi, scPharmaceuticals, Tricog Health, and Urovant Pharmaceuticals; and has received speaker fees from Bayer, Boehringer Ingelheim, Cytokinetics, Lexicon, and Roche Diagnostics. Dr. Mentz has received research support and\/or honoraria from Novartis, Abbott, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Fast BioMedical, Gilead, Innolife, Eli Lilly, Medtronic, Medable, Merck, Novo Nordisk, Pharmacosmos, Relypsa, Respicardia, Roche, Sanofi, Vifor, Windtree Therapeutics, and Zoll.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}